Contact this trialFirst, we need to learn more about you.
Azeliragon + Chemotherapy for Breast Cancer
Recruiting1 awardPhase 1 & 2
Washington, District of Columbia
This trial is testing azeliragon, a drug that may reduce heart and brain damage caused by chemotherapy. It targets patients receiving anthracycline chemotherapy, which can harm the heart and cause cognitive decline. Azeliragon works by blocking a pathway involved in inflammation and cell damage. It is being studied as a potential treatment to slow disease progression in patients with mild Alzheimer's Disease.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service